What was Kailera Therapeutics' stock performance and IPO size on its Nasdaq debut?

Kailera Therapeutics' shares surged 62.5% in their Nasdaq debut after closing a $625 million U.S. initial public offering; the company sold roughly 39 million shares priced at $16 (the top end of its marketed range), and the stock opened at $26 per share.

What is Kailera's lead drug candidate, its mechanism, development stage, and what other pipeline asset is mentioned?

Kailera's lead product is KAI-9531, a once-weekly injectable targeting GLP-1/GIP, currently in global phase 3 trials; the company is also developing KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist.

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Apr 17, 2026

Kailera Therapeutics shares surged 62.5% in its Nasdaq IPO, raising $625 million amid intense competition in the weight-loss drug market dominated by GLP-1 therapies.

reuters

2026-04-17

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

Kailera soars over 60% in Nasdaq debut as weight-loss drug race heats up

FAQ